Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer
Status:
Completed
Trial end date:
2018-09-26
Target enrollment:
Participant gender:
Summary
This is a Phase 4, single-arm, open-label, multicenter study to assess the safety and
efficacy of pertuzumab in combination with trastuzumab and docetaxel for the treatment of
participants with human epidermal growth factor receptor 2 (HER2)-positive advanced (locally
recurrent, unresectable, or metastatic) breast cancer.